Can Amgen Find a New Engine?

Amgen's string of misfortunes has highlighted the group's need to find an alternative growth engine--one which will, necessarily, look very different from the current anemia franchise. The biotech is leaning too heavily on osteoporosis and cancer candidate denosumab.